Nuvilex (NASDAQ:PMCB) Stock Rating Upgraded by Wall Street Zen

Nuvilex (NASDAQ:PMCB) was upgraded by Wall Street Zen to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Nuvilex has an average rating of “Sell”.

Nuvilex Price Performance

Shares of NASDAQ PMCB opened at $0.82 on Friday. The company has a market capitalization of $8.30 million, a price-to-earnings ratio of -0.59 and a beta of 0.04. The business has a 50-day moving average of $0.87 and a two-hundred day moving average of $0.92. Nuvilex has a 1 year low of $0.63 and a 1 year high of $1.90.

Nuvilex (NASDAQ:PMCB) last released its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

Insider Buying and Selling at Nuvilex

In other news, CEO Joshua Silverman bought 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was purchased at an average cost of $0.83 per share, with a total value of $33,200.00. Following the transaction, the chief executive officer directly owned 416,250 shares in the company, valued at $345,487.50. This trade represents a 10.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders bought 110,000 shares of company stock valued at $89,000. 10.33% of the stock is currently owned by insiders.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.